Tamoxifen is a selective estrogen receptor modulator and its use in estrogen receptor positive breast cancer patients can significantly reduce breast cancer mortality [
1]. The use of tamoxifen is associated with several ocular toxicities: keratopathy, cataract, optic neuritis, retinopathy and maculopathy [
1]. These conditions are reported to be dose-dependent and are reversible if the symptoms are recognized on time and tamoxifen treatment is stopped [
1‐
4]. …